JP2007528369A - ３，３，１４，１４−テトラメチルヘキサデカン−１，１６−ジオイック酸の投与法 - Google Patents

３，３，１４，１４−テトラメチルヘキサデカン−１，１６−ジオイック酸の投与法 Download PDF

Info

Publication number
JP2007528369A
JP2007528369A JP2006546479A JP2006546479A JP2007528369A JP 2007528369 A JP2007528369 A JP 2007528369A JP 2006546479 A JP2006546479 A JP 2006546479A JP 2006546479 A JP2006546479 A JP 2006546479A JP 2007528369 A JP2007528369 A JP 2007528369A
Authority
JP
Japan
Prior art keywords
day
treatment
human subject
tetramethylhexadecane
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006546479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007528369A5 (enExample
Inventor
ヤコブ・バル−タナ
アイホー・ビーカースキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syndromex Ltd
Original Assignee
Syndromex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndromex Ltd filed Critical Syndromex Ltd
Publication of JP2007528369A publication Critical patent/JP2007528369A/ja
Publication of JP2007528369A5 publication Critical patent/JP2007528369A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006546479A 2003-12-30 2004-12-30 ３，３，１４，１４−テトラメチルヘキサデカン−１，１６−ジオイック酸の投与法 Pending JP2007528369A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53363903P 2003-12-30 2003-12-30
PCT/IL2004/001185 WO2005062718A2 (en) 2003-12-30 2004-12-30 Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid

Publications (2)

Publication Number Publication Date
JP2007528369A true JP2007528369A (ja) 2007-10-11
JP2007528369A5 JP2007528369A5 (enExample) 2008-02-21

Family

ID=34738867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006546479A Pending JP2007528369A (ja) 2003-12-30 2004-12-30 ３，３，１４，１４−テトラメチルヘキサデカン−１，１６−ジオイック酸の投与法

Country Status (6)

Country Link
US (1) US20090018199A1 (enExample)
EP (1) EP1699448A4 (enExample)
JP (1) JP2007528369A (enExample)
KR (1) KR20070015114A (enExample)
CA (1) CA2550943A1 (enExample)
WO (1) WO2005062718A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013067593A (ja) * 2011-09-26 2013-04-18 Wakayama Medical Univ オンコスタチンｍ受容体シグナリング制御によるメタボリック症候群の治療

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
US10479752B2 (en) 2011-12-08 2019-11-19 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
US10512624B2 (en) * 2016-11-30 2019-12-24 Syndromex Ltd. Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58131934A (ja) * 1981-12-15 1983-08-06 イッサム・リサーチ・デベロップメント・コンパニー・オブ・ザ・ヘベリュー・ユニバーシティー・オブ・エルサレム 直鎖α，ω―ジカルボン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3423166A1 (de) * 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) * 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
DE4224670A1 (de) * 1992-07-25 1994-01-27 Boehringer Mannheim Gmbh Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
IL119971A (en) * 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58131934A (ja) * 1981-12-15 1983-08-06 イッサム・リサーチ・デベロップメント・コンパニー・オブ・ザ・ヘベリュー・ユニバーシティー・オブ・エルサレム 直鎖α，ω―ジカルボン酸誘導体
JPH069385A (ja) * 1981-12-15 1994-01-18 Yissum Res Dev Co Of Hebrew Univ Of Jerusalem 肥満症、高脂質血症および糖尿病の治療用医薬組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013067593A (ja) * 2011-09-26 2013-04-18 Wakayama Medical Univ オンコスタチンｍ受容体シグナリング制御によるメタボリック症候群の治療

Also Published As

Publication number Publication date
WO2005062718A2 (en) 2005-07-14
EP1699448A2 (en) 2006-09-13
US20090018199A1 (en) 2009-01-15
EP1699448A4 (en) 2010-11-03
CA2550943A1 (en) 2005-07-14
WO2005062718A3 (en) 2005-11-10
KR20070015114A (ko) 2007-02-01

Similar Documents

Publication Publication Date Title
Duleba Medical management of metabolic dysfunction in PCOS
CA2358632C (en) Drug combinations comprising (e)-7-¬4-(4-fluorophenyl)-6-isopropyl-2-¬methyl(methylsulfonyl)amino|pyrimidin-5-yl|(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
KR20070098849A (ko) 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
Krukemyer et al. Lovastatin: a new cholesterol‐lowering agent
US20120014907A1 (en) Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
JP2020536866A (ja) Ａｃｃ阻害剤を含む併用療法
Cardoso et al. New drugs for non‐alcoholic steatohepatitis
Basak et al. An overview on management of diabetic dyslipidemia
JP2019172697A (ja) ω３ペンタエン酸組成物および使用方法
AU2020244278A1 (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
JP2007528369A (ja) ３，３，１４，１４−テトラメチルヘキサデカン−１，１６−ジオイック酸の投与法
US20070197602A1 (en) Combined pharmaceutical composition
KR20140074268A (ko) 고순도 epa를 함유하는 항비만제
Shimpi et al. Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
JP2007528369A5 (enExample)
KR20030010750A (ko) 베타블록커 및 임의로 콜레스테롤 저하제를 포함하는신규한 제제
SK11092001A3 (sk) Kombinácia vzájomne nereagujúcich liečiv obsahujúca inhibítor hmg-coa reduktázy a inhibítor, induktor alebo substrát p450 izoenzýmu 3a4
ZA200105838B (en) Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-YL] (3R,5S) -3,5-dihydroxyhept-6-enoic acid and an inhibitor inducer or substrate of P450 isoenzyme 3A4.
Maki Pathophysiology and Management of Dyslipidemias Associated with Obesity, Type 2 Diabetes, and Other Insulin-Resistant States
HK1041817B (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110927